Article
New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
1 Nov 2014
Abstract excerpt
INTRODUCTION: The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations at positions 140 and 148. The impact of a single N155H mutation to DTG resistance is described to be minor....
Topics
Join the communities discussing this publication.